Sanomics is a pioneering genomics technology company based in Hong Kong. Using a new generation of proprietary technologies, Sanomics offers blood-based genomics testing for cancer patients. Genomics biomarker is essential to personalized management of cancer. A classic example is the identification of epidermal growth factor receptor mutation (EGFR mut) as biomarker for the use of EGFR targeted therapy for lung cancer patients. These oncogenic mutations occur in tumor cell and genomics testing is routinely done in the tumor biopsy. However, feasibility and quality of biopsy are not always possible nor available. As an alternative, we are now capable of detecting the abnormal mutation from plasma DNA. Presence of absence of the abnormal mutation will help doctor to determine the treatment strategy.Our first product is Droplet Digital Polymerase Chain Reaction for the detection of EGFR mutations from plasma cell-free DNA of patients with clinical symptoms or diagnosis of lung cancer. Doctors may select patients with suspected or confirmed lung cancer and send a tube of blood sample to Sanomics to perform the p-EGFR test. Our company will determine the status of EGFR mutation from the extracted cell-free DNA. This will provide an efficient and low risk method to determine this important genomics information for clinical management.